miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression.

Kopp, Florian; Oak, Prajakta S; Wagner, Ernst; Roidl, Andreas

Kopp, Florian; Oak, Prajakta S; Wagner, Ernst; Roidl, Andreas.

Affiliation

Kopp F; Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.

PLoS One ; 7(11): e50469, 2012.

Article in En | MEDLINE | ID: mdl-23209748

Subject(s)

Antineoplastic Agents/pharmacology; Breast Neoplasms/metabolism; Doxorubicin/pharmacology; MicroRNAs/metabolism; Polycomb Repressive Complex 1/metabolism; Receptor, trkB/metabolism; Breast Neoplasms/genetics; Cell Line, Tumor; Evolution, Molecular; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; MicroRNAs/genetics; Polycomb Repressive Complex 1/genetics; Receptor, trkB/genetics; Reverse Transcriptase Polymerase Chain Reaction

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Doxorubicin / Receptor, trkB / MicroRNAs / Polycomb Repressive Complex 1 / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2012 Document type: Article Affiliation country: Germany Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google